Annexon, Inc.

Biotechnology • Healthcare • Brisbane, CA, United States • ANNX (NMS)

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Annexon (NASDAQ:ANNX) Stock Price Down 6.9% - Should You Sell? - MarketBeat

MarketBeat • Jan 2

Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development - Yahoo Finance

Yahoo Finance • Dec 17

Latham & Watkins Advises on Annexon’s US$75 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP

Latham & Watkins LLP • Nov 13

Annexon stock rises after director purchases shares (ANNX:NASDAQ) - Seeking Alpha

Seeking Alpha • Nov 20

Annexon Inc.: New Coverage Initiates Buy Rating – Stock on the Rise - StocksToTrade

StocksToTrade • Dec 21

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Annexon, Inc. had layoffs?

No layoff events have been recorded for Annexon, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Annexon, Inc. have?

Annexon, Inc. has approximately 99 employees.

What industry is Annexon, Inc. in?

Annexon, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Annexon, Inc. a publicly traded company?

Yes, Annexon, Inc. is publicly traded under the ticker symbol ANNX on the NMS. The company has a market capitalization of approximately $0.77 billion.

Where is Annexon, Inc. headquartered?

Annexon, Inc. is headquartered in Brisbane, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.